Regeneron Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Regeneron Pharmaceuticals
REGN Stock  USD 803.17  19.52  2.49%   
Regeneron Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Regeneron Pharmaceuticals' valuation are provided below:
Gross Profit
6.4 B
Profit Margin
0.3141
Market Capitalization
84.9 B
Enterprise Value Revenue
5.3649
Revenue
14.3 B
We have found one hundred twenty available trending fundamental ratios for Regeneron Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Regeneron Pharmaceuticals' recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 15th of February 2026, Market Cap is likely to grow to about 40.3 B. Also, Enterprise Value is likely to grow to about 40.3 B

Regeneron Pharmaceuticals Total Revenue

15.06 Billion

Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 570.9 M, Interest Expense of 24.8 M or Total Revenue of 15.1 B, as well as many indicators such as Price To Sales Ratio of 5.35, Dividend Yield of 0.0037 or PTB Ratio of 5.05. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Regeneron Stock
Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Regeneron Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets42.6 B40.6 B16.7 B
Slightly volatile
Other Current Liabilities3 B2.9 B1 B
Slightly volatile
Total Current Liabilities4.6 B4.4 B2 B
Slightly volatile
Total Stockholder Equity32.8 B31.3 B12.5 B
Slightly volatile
Property Plant And Equipment Net5.4 B5.1 B2.6 B
Slightly volatile
Cash3.3 B3.1 B1.6 B
Slightly volatile
Non Current Assets Total23.7 B22.5 B7.8 B
Slightly volatile
Non Currrent Assets Other1.9 B1.8 B431.1 M
Slightly volatile
Cash And Short Term Investments9 B8.6 B4.4 B
Slightly volatile
Net Receivables6 B5.7 B3.1 B
Slightly volatile
Common Stock Shares Outstanding78 M108.6 M104.7 M
Slightly volatile
Liabilities And Stockholders Equity42.6 B40.6 B16.7 B
Slightly volatile
Non Current Liabilities Total5.2 B4.9 B2.2 B
Slightly volatile
Other Current Assets498.5 M474.8 M296.9 M
Slightly volatile
Total Liabilities9.8 B9.3 B4.2 B
Slightly volatile
Total Current Assets18.9 B18 B9 B
Slightly volatile
Short and Long Term Debt Total2.8 B2.7 B1.5 B
Slightly volatile
Accounts Payable986 M939 M368.8 M
Slightly volatile
Short Term Debt41.3 M43.5 M374 M
Pretty Stable
Property Plant And Equipment Gross8.1 B7.7 B3.3 B
Slightly volatile
Short Term Investments5.8 B5.5 B2.3 B
Slightly volatile
Inventory3.4 B3.2 B1.3 B
Slightly volatile
Other Liabilities854.7 M814 M590.7 M
Slightly volatile
Long Term Debt2.1 B2 B1.2 B
Slightly volatile
Common Stock Total Equity91.3 K115 K98 K
Slightly volatile
Common Stock93.5 K115 K98.1 K
Slightly volatile
Property Plant Equipment4.5 B4.3 B2.4 B
Slightly volatile
Current Deferred Revenue580.6 M553 M349.8 M
Slightly volatile
Net Tangible Assets26.3 B25 B11 B
Slightly volatile
Long Term Debt Total2.4 B2.3 B1.1 B
Slightly volatile
Capital Surpluse12 B11.4 B5.6 B
Slightly volatile
Long Term Investments10.8 B10.3 B3.7 B
Slightly volatile
Non Current Liabilities Other2.1 B2 B770.7 M
Slightly volatile
Short and Long Term Debt140.8 M149 M130.6 M
Slightly volatile
Capital Lease Obligations761.4 M828 M627.3 M
Slightly volatile
Net Invested Capital34.9 B33.2 B12.6 B
Slightly volatile
Net Working Capital12.2 B13.7 B7.9 B
Slightly volatile
Capital Stock80 K90 K98.2 K
Slightly volatile

Regeneron Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization570.9 M543.7 M219.3 M
Slightly volatile
Total Revenue15.1 B14.3 B7.6 B
Slightly volatile
Other Operating Expenses11.3 B10.8 B4.9 B
Slightly volatile
Cost Of Revenue2.2 B2.1 B923.9 M
Slightly volatile
Total Operating Expenses9.1 B8.7 B4 B
Slightly volatile
Research Development6.1 B5.9 B2.6 B
Slightly volatile
Selling General Administrative2.8 B2.7 B1.4 B
Slightly volatile
Tax Provision587.2 M725.8 M553.2 M
Very volatile
Interest Income752.6 M716.8 M180.6 M
Slightly volatile
Reconciled Depreciation342.5 M543.7 M244.9 M
Slightly volatile
Non Recurring204.1 M229.6 M250.6 M
Slightly volatile

Regeneron Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.6 B2.5 B1.4 B
Slightly volatile
Depreciation570.9 M543.7 M219.3 M
Slightly volatile
Capital Expenditures943.3 M898.4 M479.6 M
Slightly volatile
End Period Cash Flow3.3 B3.1 B1.6 B
Slightly volatile
Stock Based Compensation1 B993.7 M515.6 M
Slightly volatile
Issuance Of Capital Stock604.1 M635.9 M643 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.355.629112.0743
Slightly volatile
Dividend Yield0.00370.00410.0045
Slightly volatile
PTB Ratio5.052.5839.066
Slightly volatile
Days Sales Outstanding77.44146132
Slightly volatile
Book Value Per Share314299116
Slightly volatile
Stock Based Compensation To Revenue0.10.06930.0896
Slightly volatile
Capex To Depreciation1.961.65242.86
Slightly volatile
PB Ratio5.052.5839.066
Slightly volatile
EV To Sales5.325.600411.7918
Slightly volatile
Inventory Turnover0.620.65631.3489
Slightly volatile
Days Of Inventory On Hand584556395
Slightly volatile
Payables Turnover3.722.23722.7936
Slightly volatile
Sales General And Administrative To Revenue0.210.230.2501
Pretty Stable
Research And Ddevelopement To Revenue0.390.40790.471
Slightly volatile
Capex To Revenue0.05950.06260.0785
Slightly volatile
Cash Per Share86.3882.267736.5637
Slightly volatile
Payout Ratio0.06580.0740.0808
Slightly volatile
Days Payables Outstanding155163132
Very volatile
Intangibles To Total Assets0.01810.0310.0097
Slightly volatile
Current Ratio3.924.12555.4136
Slightly volatile
Tangible Book Value Per Share301287113
Slightly volatile
Receivables Turnover2.372.49832.7785
Slightly volatile
Graham Number565538244
Slightly volatile
Shareholders Equity Per Share314299116
Slightly volatile
Debt To Equity0.08220.08660.1808
Slightly volatile
Capex Per Share9.028.58894.4195
Slightly volatile
Revenue Per Share14413769.9046
Slightly volatile
Interest Debt Per Share27.626.287813.4771
Slightly volatile
Debt To Assets0.06340.06670.1075
Slightly volatile
Operating Cycle737702504
Slightly volatile
Price Book Value Ratio5.052.5839.066
Slightly volatile
Days Of Payables Outstanding155163132
Very volatile
Dividend Payout Ratio0.06580.0740.0808
Slightly volatile
Ebt Per Ebit1.411.46191.028
Slightly volatile
Company Equity Multiplier1.881.29761.5679
Slightly volatile
Long Term Debt To Capitalization0.05680.05970.1242
Slightly volatile
Total Debt To Capitalization0.07570.07970.1363
Slightly volatile
Debt Equity Ratio0.08220.08660.1808
Slightly volatile
Quick Ratio3.223.39284.9214
Slightly volatile
Net Income Per E B T1.090.86120.8803
Very volatile
Cash Ratio0.680.71381.6974
Slightly volatile
Days Of Inventory Outstanding584556395
Slightly volatile
Days Of Sales Outstanding77.44146132
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.310.81960.9069
Pretty Stable
Price To Book Ratio5.052.5839.066
Slightly volatile
Fixed Asset Turnover1.552.80112.786
Very volatile
Debt Ratio0.06340.06670.1075
Slightly volatile
Price Sales Ratio5.355.629112.0743
Slightly volatile
Asset Turnover0.280.35360.5118
Slightly volatile
Price Fair Value5.052.5839.066
Slightly volatile

Regeneron Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.3 B38.4 B37.8 B
Slightly volatile
Enterprise Value40.3 B38.4 B37.7 B
Slightly volatile

Regeneron Fundamental Market Drivers

Forward Price Earnings17.8253
Cash And Short Term Investments8.6 B

Regeneron Upcoming Events

2nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
2nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Regeneron Pharmaceuticals Financial Statements

Regeneron Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Regeneron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue553 M580.6 M
Total Revenue14.3 B15.1 B
Cost Of Revenue2.1 B2.2 B
Stock Based Compensation To Revenue 0.07  0.10 
Sales General And Administrative To Revenue 0.23  0.21 
Research And Ddevelopement To Revenue 0.41  0.39 
Capex To Revenue 0.06  0.06 
Revenue Per Share 137.12  143.98 
Ebit Per Revenue 0.25  0.26 

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Regeneron Stock

  0.62DRMA Dermata TherapeuticsPairCorr
  0.61VANI Vivani MedicalPairCorr
  0.57RAC Race OncologyPairCorr
  0.5OSE OSE Pharma SAPairCorr
  0.46ABNX Abionyx Pharma SAPairCorr
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
How To Invest In Regeneron
Details
Is Regeneron Stock a good investment?
Details
What is Regeneron Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Will Biotechnology sector continue expanding? Could Regeneron diversify its offerings? Factors like these will boost the valuation of Regeneron Pharmaceuticals. Anticipated expansion of Regeneron directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regeneron Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.03)
Dividend Share
3.52
Earnings Share
41.44
Revenue Per Share
137.121
Quarterly Revenue Growth
0.025
Investors evaluate Regeneron Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regeneron Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regeneron Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Regeneron Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regeneron Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regeneron Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY